AI Summary
This article presents findings from a single-center, single-arm, phase 2/3 imaging trial comparing the diagnostic performance of 68Ga-RM2 PET-MRI versus MRI alone in patients with biochemical recurrence of prostate cancer. The study suggests that 68Ga-RM2 PET-MRI is more effective in evaluation than MRI alone. The article calls for further comparative studies with PSMA-targeted PET to better understand the expression patterns of GRPR and PSMA in these patients.
68Ga-RM2 PET–MRI showed better diagnostic performance than MRI alone in patients with biochemical recurrence of prostate cancer. Further prospective comparative studies with PSMA-targeted PET are needed to gain a better understanding of GRPR and PSMA expression patterns in these patients.